Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.230
+0.040 (1.25%)
Jun 18, 2026, 9:55 AM HKT
Market Cap1.16B -80.9%
Revenue (ttm)37.13M -53.6%
Net Income-146.26M
EPS-0.40
Shares Out 364.59M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume400
Open3.250
Previous Close3.190
Day's Range3.230 - 3.250
52-Week Range2.400 - 10.580
Betan/a
AnalystsStrong Buy
Price Target38.88 (+1,103.72%)
Earnings DateAug 28, 2026

About HKG:2563

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injections for metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis indications; and Utidelone capsules for metastasis breast cancer, triple-negative breast cancer adjuvant i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 134
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2563
Full Company Profile

Financial Performance

In 2025, HKG:2563's revenue was 33.36 million, a decrease of -53.57% compared to the previous year's 71.87 million. Losses were -131.44 million, -8.58% less than in 2024.

Financial numbers in CNY Financial Statements